Evidence map›Paper›PMID 40733590›Full record

ArticleViruses2025

The Unprotected: Measles Seroprevalence in Children During the First Two Years of Life.

Sophie Rettenbacher-Riefler, Ina Holle, Mareike Wollenweber

Abstract read
In one paragraph

Article in Viruses, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Sophie Rettenbacher-RieflerDepartment for Microbiology, Public Health Agency of Lower Saxony, 30449 Hanover, Germany.
Ina HolleDepartment for Infectious Disease Epidemiology and Surveillance, Public Health Agency of Lower Saxony, 30449 Hanover, Germany.
Mareike WollenweberDepartment for Infectious Disease Epidemiology and Surveillance, Public Health Agency of Lower Saxony, 30449 Hanover, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Young children are particularly vulnerable to measles infections. Investigating the gap between the waning of maternal antibodies and onset of vaccination-induced immunity via seroprevalence studies can be hampered by recruiting enough young-aged participants. We present measles IgG-antibody results from 2148 patients aged 0 to 2 years, who were hospitalized with acute aseptic meningitis or encephalitis in Lower Saxony or Bremen. Measles serology was performed for differential diagnostics clarification of neurotropic pathogens, during syndromic surveillance between 2006 and 2024. At birth, 79% of children presented with measles IgG-antibodies, but only 30% of three-month-old patients and 11% of five-month-olds. From 0 to 10 months, seropositivity declined monthly by 8%. Over 95% of children aged six to 11 months were unprotected. From 11 months onwards, measles seroprevalence increased, reaching 80-90% towards the end of the second year of life. Our results indicate an absence of maternal measles IgG antibodies after nine months of age and that vaccination starts around 11 months of age; however, not all children had received vaccination by their second birthday. These findings confirm the current recommendation to advance first measles vaccination to nine months in high-exposure settings and support efforts to increase vaccination rates in small children and young adults.

Indexed as

Antibodies, ViralMeaslesChild, PreschoolFemaleGermanyHumansImmunity, Maternally-AcquiredImmunoglobulin GInfantInfant, NewbornMaleMeasles VaccineMeasles virusSeroepidemiologic StudiesVaccinationAntibodies, ViralImmunoglobulin GMeasles Vaccineeradicationmaternal antibodiesmeaslesseroprevalence

Identifiers

PMID40733590
PMCPMC12300673

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.